Lantern Pharma (LTRN) investor relations material

Executive summary

• Established Open-Medicine AI (OMAI) as a separate, wholly owned company with commercial licensing agreements, plans for external funding, and a potential public listing.

• Advanced AI-driven oncology pipeline, including LP-300, LP-184 (zirdafulven), and LP-284, with multiple clinical trials and regulatory clearances in the US and Europe.

• Achieved key milestones: EMA clearance for LP-184 bladder cancer trial, FDA clearance for LP-184 in triple-negative breast cancer, and expanded patent estate including a three-gene signature for patient selection.

• LP-300 HARMONIC trial in never-smoker NSCLC (EGFR exon 21 L858R) showed median PFS of 8.9 months, 77% clinical benefit rate, and tumor reduction in over 70% of evaluable patients.

• Net losses continue as R&D and G&A expenses remain high, with no revenue recognized in the period.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $7.4 million as of June 30, 2026, down from $10.1 million at year-end 2025.

• Raised $4.4 million in gross proceeds from a registered direct offering in May 2026.

• Q2 2026 loss from operations was $3.5 million, a 25% decrease year-over-year.

• Net loss for Q2 2026 was $7.1 million ($0.57/share), up from $4.3 million ($0.40/share) in Q2 2025, mainly due to non-cash warrant expenses.

• R&D expenses fell 42% year-over-year to $1.8 million; G&A expenses rose 8% to $1.7 million.

Outlook and guidance

• OMAI plans to raise capital and potentially list publicly, with a dedicated informational call scheduled for September 2026.

• Plans to enroll 15–16 additional patients in the LP-300 trial under the amended protocol over the next 4–6 months.

• Continued focus on advancing AI-driven drug candidates and expanding clinical trials in oncology.

• Intends to pursue additional capital raises, collaborations, and partnerships to extend operating runway.

• Substantial doubt exists about the ability to continue as a going concern without significant additional funding.